Understanding Clinical Equivalence In Medical Devices: Key Insights From The EU MDR

Clinical equivalence remains one of the most technically demanding and strategically significant pathways under the European Union Medical Device Regulation (EU MDR 2017/745). For manufacturers of Class III and implantable medical devices, demonstrating clinical equivalence can reduce the need for new clinical investigations provided stringent regulatory criteria are fully satisfied.

Under the EU MDR framework, equivalence is no longer a simplified comparison exercise. It is a structured, evidence-based regulatory strategy requiring deep technical documentation, clinical evaluation expertise, and alignment with notified body expectations.

Maven Regulatory Solutions provides specialized regulatory intelligence and medical device compliance strategies to support manufacturers in building defensible equivalence justifications aligned with EU MDR Article 61 and Annex XIV requirements.

Regulatory Foundation of Clinical Equivalence Under EU MDR

Clinical equivalence is primarily governed by:

• Article 61 (Clinical Evaluation)
• Annex XIV (Part A – Clinical Evaluation)
• Article 2(48) – Definition of Clinical Data
• MDCG 2020-5 Guidance on Equivalence
• General Safety and Performance Requirements (Annex I)

Compared to the former Medical Device Directive (MDD 93/42/EEC), the MDR significantly strengthens equivalence criteria. Manufacturers must now demonstrate:

• Access to technical documentation of the equivalent device
• Scientific justification of similarity
• Comprehensive risk-based assessment
• Clear demonstration that no clinically significant differences exist

For Class III and implantable devices, Article 61(4) permits exemption from clinical investigations only when equivalence is robustly justified and contractually supported (if relying on another manufacturer’s device).

What Is Clinical Equivalence?

Clinical equivalence means that a new medical device demonstrates comparable safety, performance, and clinical outcomes to a legally marketed reference device based on three core pillars:

1. Technical Characteristics
2. Biological Characteristics
3. Clinical Characteristics

All three dimensions must be simultaneously satisfied.

Failure in any one dimension may invalidate the equivalence claim.

Three Pillars of Demonstrating Equivalence Under MDR

1. Technical Characteristics

Technical equivalence requires detailed comparison of:

Under MDR scrutiny, notified bodies require traceable documentation linking technical characteristics to risk management (ISO 14971) and GSPR compliance.

2. Biological Characteristics

Biological equivalence ensures comparable interaction with human tissue and body fluids.

Unlike previous directives, MDR does not allow broad assumptions regarding material similarity. Scientific literature, biological evaluation reports (BER), and toxicological risk assessments must support all claims.

3. Clinical Characteristics

Clinical equivalence demands alignment across:

• Same intended medical indication
• Comparable patient population
• Similar disease severity and stage
• Equivalent anatomical site
• Comparable user profile (HCP vs lay user)

Clinical data sources may include:

• Published peer-reviewed literature
• Post-market surveillance data
• PMCF studies
• Registry data
• Vigilance records

A Clinical Evaluation Report (CER) prepared in accordance with Annex XIV and MEDDEV 2.7/1 Rev 4 principles (where applicable) remains central to demonstrating equivalence.

Additional MDR Requirements Strengthening Equivalence

Since the MDR transition and subsequent MDCG updates, manufacturers must also consider:

Access to Technical Documentation

If equivalence is claimed to a competitor’s device, manufacturers must have sufficient access to technical data. Without contractual access, notified bodies typically reject equivalent claims for Class III and implantable devices.

Risk Management Integration

Equivalence must align with:

• ISO 14971 risk management file
• Benefit-risk analysis
• Residual risk evaluation
• Post-market clinical follow-up (PMCF) strategy

Post-Market Clinical Follow-Up (PMCF)

Even when equivalence is established, PMCF activities remain mandatory under MDR. Equivalence does not eliminate lifecycle clinical obligations.

Comparison: MDD vs MDR Clinical Equivalence

The regulatory burden has substantially increased under MDR, making expert regulatory strategy essential.

Strategic Considerations for Manufacturers

When developing an equivalent-based regulatory pathway, manufacturers should:

• Conduct early regulatory gap analysis
• Perform side-by-side technical comparison matrix
• Document scientific justification for all differences
• Align CER with PMS and PMCF plans
• Anticipate notified body technical review depth
• Integrate EUDAMED data traceability

A poorly substantiated equivalence claim can lead to:

• Notified body non-conformities
• Clinical investigation requirements
• Delayed CE marking
• Increased regulatory costs

Trending Regulatory Focus Areas (2025 Update)

Recent regulatory scrutiny trends include:

• Increased notified body rejection of literature-only equivalence
• Stronger evaluation of software-driven medical devices (SaMD)
• Cybersecurity risk integration into clinical evaluation
• Real-world evidence (RWE) acceptance considerations
• Enhanced vigilance trend reporting under MDR Article 88

Manufacturers must ensure their equivalence strategy incorporates digital health integration, AI-driven devices where applicable, and lifecycle clinical data governance.

Frequently Asked Questions (FAQ)

1. Can clinical equivalence fully replace a clinical investigation under EU MDR?

Only in limited cases under Article 61(4), primarily for Class III and implantable devices, and only when strict criteria are met.

2. Is literature alone sufficient for equivalence?

In most high-risk cases, literature alone is insufficient without access to technical documentation of the equivalent device.

3. Does equivalence remove PMCF requirements?

No. Post-Market Clinical Follow-Up remains mandatory under Annex XIV Part B.

4. What is the biggest reason equivalence claims fail?

Insufficient technical documentation access and inadequate biological justification.

5. How does MDCG 2020-5 impact equivalence strategy?

It provides detailed interpretation guidance on assessing technical, biological, and clinical similarity and strengthens notified body expectations.

Conclusion

Clinical equivalence under EU MDR is no longer a simplified regulatory shortcut it is a scientifically rigorous, documentation-intensive regulatory pathway. When properly executed, it can optimize clinical development timelines, reduce unnecessary clinical investigations, and maintain full compliance with EU MDR 2017/745 requirements.

However, the increased scrutiny from notified bodies demands deep regulatory expertise, structured technical comparison, and lifecycle clinical data integration.

Maven Regulatory Solutions supports medical device manufacturers with comprehensive EU MDR clinical evaluation strategy, equivalence justification documentation, regulatory gap analysis, CER development, and notified body readiness preparation ensuring robust, defensible compliance aligned with the evolving European regulatory landscape.